Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Phase II efficacy results for ABT-436 in alcohol-dependent subjects

Oct. 3, 2016

NIH dopamine D3 receptor antagonist VK-4-116 active in substance abuse models

Sep. 12, 2016

Insys Therapeutics enrolls first patient in phase II trial of canabidiol

Aug. 19, 2016

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Aug. 17, 2016

Embera Neurotherapeutics receives grant to continue development of drug for cocaine addition

July 27, 2016

Cerecor announces research grant for the development of CERC-501

July 27, 2016

Cerecor awarded grant from NIAAA

July 21, 2016

Addex Therapeutics reports positive results on ADX-71441

June 10, 2016

FDA awards fast track designation to Indivior's RBP-6000 buprenorphine monthly depot

May 27, 2016

FDA approves Probuphine for opioid dependence

May 27, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...